Charles River Laboratories International
Charles River Laboratories is dedicated to helping accelerate research and drug development, providing essential products and services from discovery to early development and manufacturing. They focus on creating healthier lives through world-class science, innovation, and a commitment to animal welfare, with a strong emphasis on scientific and regulatory guidance, and advancing alternatives to animal testing. Their mission is to bring vital drugs to market safely and quickly, with a responsibility to clients, patients, animals, and the scientific community.
Industries
Nr. of Employees
Very Large (1000+)
Patents
Products
Recombinant endotoxin testing reagent (animal-free)
An animal-free recombinant reagent option for endotoxin testing designed to detect endotoxin without use of animal-derived reagents.
Cell microarray screening platform using non-human protein library
High-throughput cell microarray screening platform that uses a non-human protein library to profile off-target interactions and de-risk preclinical programs for regulatory submissions.
Recombinant endotoxin testing reagent (animal-free)
An animal-free recombinant reagent option for endotoxin testing designed to detect endotoxin without use of animal-derived reagents.
Cell microarray screening platform using non-human protein library
High-throughput cell microarray screening platform that uses a non-human protein library to profile off-target interactions and de-risk preclinical programs for regulatory submissions.
Services
End-to-end IND-enabling programs including study design, GLP toxicology, regulatory documentation and submission support to interact with major regulatory agencies.
Scalable cGMP manufacturing and development services for cell and gene therapies including process development, tech transfer, and commercial production.
Provision and customization of laboratory animal models, genetically engineered mouse and rat model creation, breeding, genotyping, and cryopreservation services to support discovery and preclinical research.
Bioanalytical method development and regulated bioanalysis (PK, immunogenicity, biomarker assays) using chromatographic and mass spectrometry platforms to support preclinical and clinical programs.
Endotoxin testing, contamination screening, and PCR-based pathogen surveillance for biologics and medical-device water systems, with animal-free reagent options where available.
Advisory, adoption, and testing services for NAMs including organoids, 3D models, in silico toxicology, virtual control groups and computational modeling to support reduction of animal use.
End-to-end IND-enabling programs including study design, GLP toxicology, regulatory documentation and submission support to interact with major regulatory agencies.
Scalable cGMP manufacturing and development services for cell and gene therapies including process development, tech transfer, and commercial production.
Provision and customization of laboratory animal models, genetically engineered mouse and rat model creation, breeding, genotyping, and cryopreservation services to support discovery and preclinical research.
Bioanalytical method development and regulated bioanalysis (PK, immunogenicity, biomarker assays) using chromatographic and mass spectrometry platforms to support preclinical and clinical programs.
Endotoxin testing, contamination screening, and PCR-based pathogen surveillance for biologics and medical-device water systems, with animal-free reagent options where available.
Advisory, adoption, and testing services for NAMs including organoids, 3D models, in silico toxicology, virtual control groups and computational modeling to support reduction of animal use.
Expertise Areas
- Regulatory compliance and IND submission support
- Safety assessment and toxicology (GLP and non-GLP)
- In vivo disease modeling and oncology research
- Cell and gene therapy development and GMP manufacturing
Key Technologies
- Patient-derived xenograft (PDX) models
- Humanized mouse models
- 3D in vitro cancer models and organoids
- Next-generation sequencing (NGS)
News & Updates
Webinar scheduled for July 9, 2025, discussing innovative animal dosing methods.
Webinar scheduled for July 17, 2025, focusing on new approach methodologies in biologic development.
Webinar scheduled for June 26, 2025, on regulatory strategies for lung models.
Webinar discussing recent updates to the European Regulatory Assessment guidelines.
Eureka Blog article discussing the impact of COVID-19 on cancer research and ongoing efforts.
Eureka Blog article on the use of humanized mice models in immuno-oncology research.
Webinar scheduled for July 9, 2025, discussing innovative animal dosing methods.
Webinar scheduled for July 17, 2025, focusing on new approach methodologies in biologic development.
Webinar scheduled for June 26, 2025, on regulatory strategies for lung models.
Webinar discussing recent updates to the European Regulatory Assessment guidelines.
Eureka Blog article discussing the impact of COVID-19 on cancer research and ongoing efforts.
Eureka Blog article on the use of humanized mice models in immuno-oncology research.